Physician profile
Daniel Fischer
NPI 1538657523
$8,566.42
in general payments reported to CMS, 2019-2025
25 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.46 · 2020: $229 · 2021: $1,168 · 2022: $2,034 · 2023: $1,910 · 2024: $1,798 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,040 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,039.64 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,322.24 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,177.56 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $747.63 | 2020-2024 | Aklief, Epsolay, Twyneo |
| Genzyme Corporation | $685.54 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $663.23 | 2021-2023 | Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.04 | 2022-2024 | Spevigo, Cyltezo |
| Incyte Corporation | $570.48 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $535.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $421.78 | 2021-2025 | Sotyktu |
| Dermavant Sciences, INC. | $394.85 | 2023-2024 | Vtama |
| Pfizer INC. | $222.07 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $210.38 | 2021-2022 | |
| Ucb, INC. | $179.80 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $135.37 | 2021-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $125.72 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $121.36 | 2025 | |
| Botanix Sb INC | $93.45 | 2025 | Sofdra |
| Leo Pharma INC. | $88.77 | 2024-2025 | Adbry |
| Biofrontera INC. | $67.16 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $57.86 | 2025 | Vtama |
| Lilly USA, LLC | $45.41 | 2022 | |
| Arcutis Biotherapeutics, INC. | $30.21 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $24.14 | 2021 | |
| Epi Health, LLC | $16.88 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.